[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-376307-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-376307-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","understanding-chemotherapy-induced-thrombocytopenia-implications-for-gastrointestinal-cancer-treatment","Understanding Chemotherapy-Induced Thrombocytopenia: Implications for Gastrointestinal Cancer Treatment","","Chemotherapy-induced thrombocytopenia (CIT) is a common but underrecognized complication of systemic chemotherapy, especially in gastrointestinal (GI) cancers. In platinum- and fluoropyrimidine-based regimens, including oxaliplatin-containing protocols, CIT is linked to frequent treatment delays, dose reductions, and increased bleeding risk. This review details mechanisms, clinical implications, and management approaches for CIT in GI malignancies, including immune and marrow-related pathways. It outlines grading severity and evaluates strategies such as dose modification, platelet transfusion, and thrombopoietin receptor agonists, while discussing emerging megakaryopoiesis- and marrow-protection approaches.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/understanding-chemotherapy-induced-thrombocytopenia-implications-for-gastrointestinal-cancer-treatment/376307/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/understanding-chemotherapy-induced-thrombocytopenia-implications-for-gastrointestinal-cancer-treatment/376307.png","ImageObject",300,407,{"name":42,"@type":43},"Aldword","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-24",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is chemotherapy-induced thrombocytopenia (CIT) and why does it matter in GI cancer treatment?","Question",{"text":63,"@type":64},"CIT is a decline in platelet count caused by systemic chemotherapy. In gastrointestinal cancers, it increases bleeding risk and can lead to treatment delays or dose reductions that may reduce treatment effectiveness.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What mechanisms contribute to CIT after chemotherapy?",{"text":68,"@type":64},"CIT can arise from multiple pathways, including direct cytotoxic effects on megakaryocyte progenitors, disruption of the marrow microenvironment, thrombopoietin dysregulation, and immune-mediated platelet destruction.",{"name":70,"@type":61,"acceptedAnswer":71},"How is CIT managed in clinical practice?",{"text":72,"@type":64},"Management commonly includes chemotherapy dose modification, platelet transfusion in acute settings, and thrombopoietin receptor agonists such as romiplostim and eltrombopag to help maintain dose intensity and reduce bleeding risk.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},376307,1790464485,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":108},2336478940917,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Review  \nUnderstanding Chemotherapy-Induced Thrombocytopenia: Implications for Gastrointestinal Cancer Treatment  \nSupriya Peshin 1, Adit Dharia 2, Ehab Takrori 3, Jasmeet Kaur 4, Kannan Thanikachalam 5 and Renuka Iyer 5, *  \nReceived: 3 July 2025  \nRevised: 4 August 2025  \nAccepted: 13 August 2025  \nPublished: 14 August 2025  \nCitation: Peshin, S.; Dharia, A.; Takrori, E.; Kaur, J.; Thanikachalam, K.; Iyer, R.. Understanding ChemotherapyInduced Thrombocytopenia: Implications for Gastrointestinal Cancer Treatment. Curr. Oncol. 2025, 32, 455. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)curroncol32080455  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Norton Community Hospital, Norton, VA 24273, USA; [supriyapeshin720@gmail.com](supriyapeshin720@gmail.com)  \n2 HCA Florida Healthcare, USF Morsani College of Medicine GME Oak Hill Program, Orlando, FL 32801, USA; [aditdha@gmail.com](aditdha@gmail.com)  \n3 College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia; [etakrori@gmail.com](etakrori@gmail.com)  \n4 Fox Chase Cancer Comprehensive Center, Philadelphia, PA 19111, USA; [jasmeet.kaur@tuhs.temple.edu](jasmeet.kaur@tuhs.temple.edu)  \n5 Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA; [kannan.thanikachalam@roswellpark.org](kannan.thanikachalam@roswellpark.org)  \n* Correspondence: [renuka.iyer@roswellpark.org](renuka.iyer@roswellpark.org)  \nSimple Summary  \nMany patients with gastrointestinal cancers experience a drop in their platelet count due to chemotherapy, a condition known as chemotherapy-induced thrombocytopenia. This can increase the risk of bleeding and may force doctors to delay or reduce cancer treatment, which can affect how well it works. Unfortunately, this condition is often overlooked, and there are no clear guidelines on how best to manage it. In this article, we explain what causes this problem, how often it occurs, and what treatments are currently available. We also highlight new drugs being studied and areas where more research is needed. Our goal is to raise awareness and encourage further investigation so that doctors can better protect patients and ensure they receive the full benefit of their cancer treatments.  \nAbstract  \nChemotherapy-induced thrombocytopenia (CIT) is a common yet underrecognized complication of systemic chemotherapy, particularly in gastrointestinal (GI) cancers. Despite progress in targeted and immune-based therapies, platinum-based and fluoropyrimidine regimens, especially oxaliplatin-containing protocols, remain standard in GI cancer treatment and are linked to high rates of CIT. This complication often leads to treatment delays, dose reductions, and elevated bleeding risk. This review provides a comprehensive overview of the pathophysiology, clinical implications, and management strategies of CIT in GI malignancies. CIT arises from several mechanisms: direct cytotoxicity tomegakaryocyte progenitors, disruption of the marrow microenvironment, thrombopoietin dysregulation, and immune-mediated platelet destruction. Platinum agents, antimetabolites, and immune checkpoint inhibitors can contribute to these effects. Oxaliplatin-induced CIT may occur acutely via immune mechanisms or chronically through marrow suppression. CIT affects 20–25% of solid tumor patients, with highest rates in those receiving gemcitabine (64%), carboplatin (58%), and oxaliplatin (50%) . Within GI cancer regimens, FOLFOXIRI and S-1 plus oxaliplatin show higher CIT incidence compared to FOLFIRI and CAPIRI. Thrombocytopenia is graded by severity, from mild (Grade 1–2) to severe (Grade 3–4), and often necessitates treatment adjustments, transfusions, or supportive","cbCaidP6heznjhYo","https://ap.wps.com/l/cbCaidP6heznjhYo","pdf",1243914,16,"English","# Introduction\n## Chemotherapy regimens and CIT relevance in gastrointestinal cancers\n# Pathophysiology and mechanisms of CIT\n## Cytotoxic effects, marrow microenvironment disruption, and TPO dysregulation\n## Immune-mediated platelet destruction\n# Clinical implications in GI malignancies\n## Incidence patterns by regimen\n## Severity grading and treatment adjustments\n# Management strategies\n## Dose modification and supportive care\n## Platelet transfusion and thrombopoietin receptor agonists\n# Emerging therapies and research gaps","[{\"question\":\"What is chemotherapy-induced thrombocytopenia (CIT) and why does it matter in GI cancer treatment?\",\"answer\":\"CIT is a decline in platelet count caused by systemic chemotherapy. In gastrointestinal cancers, it increases bleeding risk and can lead to treatment delays or dose reductions that may reduce treatment effectiveness.\"},{\"question\":\"What mechanisms contribute to CIT after chemotherapy?\",\"answer\":\"CIT can arise from multiple pathways, including direct cytotoxic effects on megakaryocyte progenitors, disruption of the marrow microenvironment, thrombopoietin dysregulation, and immune-mediated platelet destruction.\"},{\"question\":\"How is CIT managed in clinical practice?\",\"answer\":\"Management commonly includes chemotherapy dose modification, platelet transfusion in acute settings, and thrombopoietin receptor agonists such as romiplostim and eltrombopag to help maintain dose intensity and reduce bleeding risk.\"}]","Understanding Chemotherapy-Induced Thrombocytopenia: Implications for Gastrointestinal Cancer Treatment | PDF",1790218156]